QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: mol.106.022624v1 70/4/1390    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Holzer, A. K. Articles by Howell, S. B. Search for Related Content PubMed PubMed Citation Articles by Holzer, A. K. Articles by Howell, S. B.

Contribution of the Major Copper Influx Transporter CTR1 to the Cellular Accumulation of Cisplatin, Carboplatin, and Oxaliplatin

Department of Medicine and the Rebecca and John Moores Cancer Center, University of California, San Diego, La Jolla, California

The goal of this study was to determine the ability of the major copper influx transporter CTR1 to mediate the cellular accumulation of cisplatin (DDP), carboplatin (CBDCA), and oxaliplatin (L-OHP). Wild-type murine embryonic fibroblasts (CTR1^+/+) and a subline in which both alleles of CTR1 were deleted (CTR1^-/-) were tested for their ability to accumulate platinum when exposed to increasing concentrations of DDP, CBDCA, or L-OHP for 1 h. They were also tested for their sensitivity to the growth-inhibitory effect of each drug. Platinum content was measured by ion-coupled plasmon mass spectroscopy. The experimental model was validated by measuring copper accumulation and cytotoxicity. CTR1^-/- cells accumulated only 5.7% as much copper as CTR1^+/+ cells during a 1-h exposure to 2 µM copper. When exposed to DDP, CBDCA, or L-OHP at 2 µM, accumulation in the CTR1^-/- cells was only 35 to 36% of that in the CTR1^+/+ cells. When tested at a 5-fold higher concentration, this deficit remained for DDP and CBDCA, but accumulation of L-OHP was no longer CTR1-dependent. There was an association between the effect of loss of CTR1 function on uptake of the platinum drugs and their cytotoxicity. The CTR1^-/- cells were 3.2-fold resistant to DDP, 2.0-fold resistant to CBDCA, but only 1.7-fold resistant to L-OHP. Thus, whereas CTR1 controls the cellular accumulation of all three drugs at low concentrations, accumulation of L-OHP is not dependent on CTR1 at higher concentrations. We conclude that L-OHP is a substrate for some other cellular entry mechanism, a feature consistent with its different clinical spectrum of activity.

Address correspondence to: Dr. Stephen B. Howell, Moores UCSD Cancer Center, 3855 Health Sciences Drive, Room 3344, La Jolla, CA 92093-0819. E-mail: showell{at}ucsd.edu

This article has been cited by other articles:

				B. G. Blair, C. A. Larson, R. Safaei, and S. B. Howell Copper Transporter 2 Regulates the Cellular Accumulation and Cytotoxicity of Cisplatin and Carboplatin Clin. Cancer Res., July 1, 2009; 15(13): 4312 - 4321. [Abstract] [Full Text] [PDF]

				N. Pabla, R. F. Murphy, K. Liu, and Z. Dong The copper transporter Ctr1 contributes to cisplatin uptake by renal tubular cells during cisplatin nephrotoxicity Am J Physiol Renal Physiol, March 1, 2009; 296(3): F505 - F511. [Abstract] [Full Text] [PDF]

				C. A. Larson, B. G. Blair, R. Safaei, and S. B. Howell The Role of the Mammalian Copper Transporter 1 in the Cellular Accumulation of Platinum-Based Drugs Mol. Pharmacol., February 1, 2009; 75(2): 324 - 330. [Abstract] [Full Text] [PDF]

				D. D. Jandial, S. Farshchi-Heydari, C. A. Larson, G. I. Elliott, W. J. Wrasidlo, and S. B. Howell Enhanced Delivery of Cisplatin to Intraperitoneal Ovarian Carcinomas Mediated by the Effects of Bortezomib on the Human Copper Transporter 1 Clin. Cancer Res., January 15, 2009; 15(2): 553 - 560. [Abstract] [Full Text] [PDF]